Cardiovascular disease: risk assessment and reduction, including lipid modification

instead of QRISK2 will require clinical systems to be updated by software developers for the impact on practice to be minimised. Public Health England issued guidance in August 2021 on using QRISK3 in NHS health checks and how to deal with the transition period (responsibility for the NHS Health Check programme has transferred to the Office for Health Improvement and Disparities, but the guidance produced by Public Health England remains current). QRISK3 requires some additional clinical information that was not required for QRISK2. However, if integrated into electronic clinical systems, QRISK3 is not likely to require additional resources over QRISK2. There may be some implementation costs as healthcare professionals become familiar with the additional information included in QRISK3 and in managing the transition period. Return to recommendations Communication about risk assessment, lifestyle changes and treatment Recommendation 1.1.16 Why the committee made the recommendation The committee agreed that the evidence did not support using lifetime CVD risk assessment tools to guide decisions on the need for statin treatment because their accuracy could not be reliably assessed. However, the committee noted that the usefulness of lifetime risk tools is primarily in communicating risk. They agreed by consensus that lifetime risk tools should
